The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...